Subtype
|
TCGA (n = 106)
|
Metabric (n = 133)
|
USO1062 (n = 79)
|
---|
HER2E
|
48 (45%)
|
71 (53%)
|
30 (38%)
|
Luminal A
|
19 (18%)
|
14 (11%)
|
26 (33%)
|
Luminal B
|
32 (30%)
|
27 (20%)
|
17 (21%)
|
Basal-like
|
7 (7%)
|
21 (16%)
|
6 (8%)
|
- Number and percentage of human epidermal growth factor receptor 2 amplified (HER2A) tumors across the prediction analysis of microarray 50 (PAM50) subtypes in The Cancer Genome Atlas (TCGA), Metabric and the USO1062 clinical trial. HER2E HER2-enriched